Regeneration of our bodies’ own cells is the subject of Biostage ™ - the new corporate name and designation for therapies in treating patients suffering from esophageal, bronchial or tracheal trauma or disease.
Biostage ™ will trade on the NASDAQ as “BSTG” effective April 1.
For years, there’s been a lot of talk about the prospects of cell biology and its impact on regenerative medicine. Billions have and continue to be spent on finding just the right formula to allow the body to heal itself from debilitating and life-threatening disease progressions.
The name, Harvard Apparatus Regenerative Technology (HART) was truly a mouthful of words. Its previous focus needed an upgrade to recognize the newest avenues of cell therapy and their potential in which are now in-place!
The new name sends a clear signal of the transformation of a company from a bioreactor and research tools company to a pioneering biotechnology firm developing bioengineered organ implants for serious and life threatening conditions.
Late Friday night, CLBS issues an 8-K rather than a press release about its delisting
CLBS closed UP +$0.0002 to $0.59. WHY is an 8-K going out instead of a press release LATE on a Friday night?
WHY - CLBS received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC notifying CLBS that for the preceding 30 consecutive business days, the common stock did NOT maintain a minimum closing bid price of $1.00 per share as required by NASDAQ Listing Rule 5550(a) (2).
CLBS has a grace period of 180 calendar days, or until August 23, 2016. When a company tries to HIDE an issue, one knows there is more BEHIND the story.
A typical Mazzo action or ploy - SELL
CYTX will validate the observations of sustained benefit in the ongoing P3 pivotal trial in the US as it is encouraging to see maintenance of the response in patients at a full two years after only a single administration!
Average values at the two-year timeframe for all four of these end points were statistically significantly improved over baseline and similar to improvements observed at one year. As with the previous studies, no safety issues related to Cytori Cell Therapy were reported.
CYTX closed -$0.01 at $0.36 and is UP in the pre-market +$0.01. News flow has picked-up and CYTX should be feeling the effect of positive results– BUY. I always love good beginnings as they foretell and fulfil the hope of … sustained improvement in four key endpoints of treatment. CYTX has FINALLY found the right mix of focus and should be … REWARDED.